Navigation Links
GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
Date:12/8/2008

LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash per share without interest and less any required withholding taxes, until 12:00 midnight EST on Friday, December 12, 2008, unless the tender offer is further extended. The tender offer was originally scheduled to expire at 12:00 midnight EST on Wednesday, December 10, 2008.

GSK has extended the tender offer in connection with the addition of SmithKline Beecham Corporation, a wholly-owned subsidiary of GSK, as a bidder, as defined in the Securities Exchange Act of 1934, as amended, with respect to the tender offer.

As of 5 p.m., EST, on December 5, 2008, approximately 3,466,063 shares of Genelabs common stock have been tendered and not withdrawn pursuant to the tender offer, representing approximately 7.8% of the outstanding shares of Genelabs common stock on a fully diluted basis.

The tender offer was commenced on November 12, 2008 pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone Acquisition Corporation and SmithKline Beecham Corporation.

All other terms and conditions of the tender offer remain the same, including the condition that, at the expiration of the offer, there have been validly tendered and not withdrawn that number of shares which, together with the number of shares, if any, then beneficially owned by GSK and its wholly-owned subsidiaries, constitutes at least 90 percent of the total number of the then outstanding Genelabs shares on a fully di
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
2. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
3. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
4. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
5. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
6. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
7. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
8. GlaxoSmithKline To Post Quarterly US Grants Report
9. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... (NSF) has awarded $6.5 million to the Center for Nanotechnology ... work regarding the societal aspects of nanotechnology for another five ... its first five-year award of $6.2 million to Arizona State ... of NSF,s initiative to support research and education on nanotechnology ...
... DIEGO, Oct. 14 Sequenom, Inc. (Nasdaq: ... a new clinical advisory board focusing on retinal ... will provide guidance to Sequenom and Sequenom Center ... of retinal care molecular diagnostics. (Logo: ...
... ... ... ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
Cached Biology Technology:Arizona State University awarded $6.5 million to study nanotechnology and society 2Arizona State University awarded $6.5 million to study nanotechnology and society 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 2Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 4Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 5The World Market for Diabetes Treatments Now Available at ReportsandReports 2The World Market for Diabetes Treatments Now Available at ReportsandReports 3The World Market for Diabetes Treatments Now Available at ReportsandReports 4The World Market for Diabetes Treatments Now Available at ReportsandReports 5The World Market for Diabetes Treatments Now Available at ReportsandReports 6The World Market for Diabetes Treatments Now Available at ReportsandReports 7The World Market for Diabetes Treatments Now Available at ReportsandReports 8The World Market for Diabetes Treatments Now Available at ReportsandReports 9
(Date:8/20/2014)... who are poor experience higher cortisol levels in pregnancy ... the stress hormone, putting them at greater risk ... new research from the University of Colorado Denver. , ... Journal of Human Biology , is the first to ... the socioeconomic status of their mothers during pregnancy. , ...
(Date:8/20/2014)... for electronically manipulating the flight muscles of moths and ... those muscles. The work opens the door to the ... emergency response. , "In the big picture, we want ... moths for use in applications such as search and ... of electrical and computer engineering at NC State and ...
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... collaboration with colleagues from UC Berkeley and StrataGent Life ... pulsed microjet system engineered to deliver protein drugs into ... penetration injection systems cause. The research was published online ... Sciences. , The effort to create needle-free drug ...
... rise to a rare genetic disease, genetics researchers have ... broader role during human development, potentially in cases of ... of researchers identified two genes that contribute to Cornelia ... an estimated one in 10,000 children. The disease varies ...
... researchers from the National Human Genome Research Institute (NHGRI), ... identified a genetic variant that is a major contributor ... the April 6, 2007 issue of the journal Science. ... variant that accounts for differences in dog size is ...
Cached Biology News:Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2Gene found for rare disorder may reveal new pathway in mental retardation 2Researchers identify gene involved in dog size 2Researchers identify gene involved in dog size 3Researchers identify gene involved in dog size 4
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: